Connect with us

NEWS

England Cut Antibiotic Use and Still Lost Ground on Resistant Infections

NHS antibiotic use in England fell 10.7% by 2025, but specified drug-resistant infections sit 25.7% above the national plan’s no-increase line.

Published

on

England recorded 21,129 antibiotic-resistant bloodstream infections in 2025, a 16.8% rise since 2019, even as NHS antibiotic use fell 10.7%. The UK Health Security Agency, publishing its ESPAUR surveillance report on 12 November 2026, put that count at an average of 406 reported cases each week.

The same report shows England has already beaten the national 5% cut in human antibiotic use. Specified drug-resistant infections, the other headline target, are 25.7% above a line that said there should be no increase at all.

The NHS Already Beat the 5% Use Cut

Total NHS antibiotic consumption in England was 15.9 defined daily doses per 1,000 inhabitants per day in 2025, down from 17.8 in 2019. That 10.7% fall also came in 6.1% below 2024, a one-year drop large enough to carry the country past the 5% ambition set for 2029.

General practice still accounted for 65.4% of NHS use and did most of the work, with GP consumption 18.8% lower than in 2019. Private community-pharmacy scripts, which sit outside the NHS total, fell 20.8% between 2024 and 2025, from 0.61 to 0.48 defined daily doses per 1,000 inhabitants per day.

Hospital use went the other way. Secondary-care consumption in 2025 was 5.4% higher than in 2019. UKHSA also warned that part of the GP decline is a counting change after the Pharmacy First service began in January 2024, moving some treatment out of practice records. Antibiotic supply through that service was 53.1% higher in 2025 than in its first 11 months, even as the share of consultations that ended with a script fell.

The Access share of use, first-choice drugs with lower resistance pressure, rose from 61% in 2019 to 65.6% in 2025. The national aim is 70% by 2029. Primary care reached 68.9%. Hospitals sat at 55%.

The last human-use plan aimed higher. A House of Commons Library briefing records that the previous human-use target of 15% by 2024 was later cut to 5% in the current plan. England has now cleared that softer bar on volume. The infection bar is a different story.

25.7% Above a Target of No Increase

The UK 5-year action plan for 2024 to 2029, published on 8 May 2024, asked England to prevent any increase in a specified set of drug-resistant infections from the 2019 to 2020 financial-year baseline. ESPAUR puts that measure 25.7% higher in 2025, driven mainly by third-generation cephalosporin-resistant E. coli and Klebsiella pneumoniae. Gram-negative bloodstream infections, the sister target, are 8% higher, largely because of Klebsiella.

NATIONAL ACTION PLAN VERSUS 2025

Target 2029 ambition 2025 result in England
Specified drug-resistant infections No increase from FY 2019 to 2020 25.7% higher
Gram-negative bloodstream infections No increase from FY 2019 to 2020 8% higher
Total human antibiotic use 5% below 2019 10.7% below 2019
Access-category share of use 70% 65.6%

The resistant-bacteraemia count did slow. Cases rose 3.2% from 20,468 in 2024 to 21,129 in 2025, about a third of the 9.3% jump from 18,732 in 2023 to 20,468 in 2024. The AMR burden rate still moved from 32.2 per 100,000 people in 2019 to 36 per 100,000 in 2025.

We can’t rely on reducing antibiotic use alone. We need to continue our work with partners globally to prevent infections from occurring in the first place, alongside exploring new treatment options.

Dr Shona Arora, Interim Chief Medical Advisor, UKHSA

Arora also said older people and the most deprived communities are hit hardest, and that leftover antibiotics should go back to a pharmacy rather than a kitchen drawer. Dame Diana Johnson, Minister for Public Health and Patient Safety, urged people to take antibiotics only when a clinician advises it, and to finish the course.

A 22.9% Rise in Blood Cultures Behind the AMR Count

The 16.8% rise in resistant bloodstream cases is not a matching leap in the share of cultures that come back resistant. Of bacteraemia episodes caused by the pathogens UKHSA uses to estimate AMR burden, 22% were resistant to one or more of the listed drugs in 2025 (21,129 of 94,181), against 21% in 2019 (18,086 of 88,160).

All bacteraemia episodes in England rose 22.9% between 2019 and 2025, to 187,254. Coagulase-negative staphylococci, common blood-culture contaminants, accounted for 44.6% of that increase, 15,583 of 34,940 extra episodes. UKHSA said the clinical meaning of that CoNS surge is still unclear.

In plain terms, England is growing older, drawing more blood cultures, and logging more bloodstream infections. The resistant fraction of the watch-list bugs barely moved. Cutting GP amoxicillin does not shrink that denominator, and farm and global reservoirs sit outside the NHS prescribing ledger Arora was pointing at.

Who Is Getting These Bloodstream Infections?

Adults aged 45 and over accounted for 89.3% of resistant cases in 2025. People aged over 74 accounted for 49.7%. Infants under 1 had the next-highest incidence after the oldest group. Males had more resistant episodes than females at every age except 1 to 4 years.

The deprivation gap on resistant bacteraemia widened while the gap on all bacteraemia narrowed. In 2019 the most deprived fifth of areas had a 29% higher resistant rate than the least deprived. In 2025 that gap was 44.2%, 44.4 against 30.8 cases per 100,000. Overall bacteraemia inequality moved the other way, from 28.4% to 23.6%.

WHERE THE 406 WEEKLY CASES FALL

Group 2025 figure
People aged over 74 49.7% of resistant cases
People aged 45 and over 89.3% of resistant cases
Most deprived areas 44.4 cases per 100,000
Least deprived areas 30.8 cases per 100,000
Asian or Asian British 42.4% of episodes resistant (46.6 per 100,000)
Black, African, Caribbean or Black British 32.8% of episodes resistant (45.2 per 100,000)
White 20.7% of episodes resistant (33.9 per 100,000)
NHS North West London ICB 63.3 per 100,000
NHS Leicester, Leicestershire and Rutland ICB 27.4 per 100,000

White patients still accounted for 87.7% of all bacteraemia, so the higher resistant percentages in Asian and Black groups sit on smaller case counts and higher rates. London’s regional rate was 44.7 per 100,000, against 30.2 in the South West. Integrated care boards scattered more than regions did. NHS North East London (51.1) and NHS Frimley (50.8) followed North West London. UKHSA said it is still working out why.

Piperacillin-Tazobactam Resistance in Klebsiella Reached 22.8%

Enterobacterales, the group that includes E. coli, K. pneumoniae and K. oxytoca, made up 85.5% of resistant bacteraemia in 2025. E. coli has held about 70% of that burden for seven years. Klebsiella is the species that is climbing.

RESISTANCE TRENDS IN THE MAIN BUGS

  • Klebsiella pneumoniae: Bloodstream episodes rose 28% between 2019 and 2025, the largest increase among priority pathogens.
  • Piperacillin-tazobactam: Resistance in K. pneumoniae rose from 15.1% in 2019 to 22.8% in 2025, almost twice the 11.9% seen in E. coli.
  • MRSA: It accounted for 7.3% of S. aureus bacteraemia; tetracycline resistance in MRSA more than doubled, from 13.3% to 31.3%.
  • Second-line drugs: Macrolide and clindamycin resistance reached about 20% in MSSA and over 40% in MRSA.
  • Carbapenemases: NDM and OXA-48-like enzymes each made up just under 40% of carbapenemase-producing organisms, with North West London at 36.6 episodes per 100,000 against 7.5 in South West London.

Those hospital-facing drugs are the ones wards still need when a urinary or abdominal infection reaches the bloodstream in an older patient. GP volume can fall and those percentages can still rise. Eighty-four of 130 acute trusts (65%) did cut Watch and Reserve use against their 2019 to 2020 baseline, and the England average for those categories finished 4.2% below that baseline. The Klebsiella numbers show why that has not closed the infection target.

Among children aged 0 to 9, 28% received at least one antibiotic in the year to March 2026, against a national aim of 27% or below. Twenty of 41 integrated care boards met it.

An £800 Million Hospital Bill and a New Fungal Alert

Deaths among people with a resistant Gram-negative bloodstream infection stayed roughly level, 2,318 in 2025 against 2,399 in 2024. The 30-day death rate was still higher when the strain was resistant.

DEATH, COST AND FUNGAL FIGURES FOR 2025

  • Resistant strains: 16.0% of patients died within 30 days, against 14.4% with a susceptible strain.
  • Carbapenemase cases: 21.2% 30-day mortality when a carbapenemase-producing organism was found in a sterile site, about 62 deaths.
  • Selected Gram-negative bacteraemia: 14.9% 30-day mortality, the lowest rate since 2019, about 8,552 deaths.
  • Hospital cost: About 53,400 Gram-negative bloodstream admissions cost NHS hospitals around £800 million in 2023 and 2024, a preliminary figure that does not isolate the extra cost of resistance.

Fungaemia rose too. The rate reached 4.1 fungal bloodstream infections per 100,000 people, 32.4% above the 3.1 recorded in 2019. Candidozyma auris, a hospital yeast that shrugs off several antifungal classes, was made notifiable in England in April 2025. UKHSA newly identified 213 patients with it in 2025, 38 with invasive infection, and 60% of those patients were tied to declared outbreaks, mostly in London and the South East.

The WHO sorts antibiotics into Access, Watch and Reserve groups so countries can watch the drugs that select for resistance fastest. England’s 65.6% Access share is better than 2019 and still short of 70%. The 406-a-week count will not turn on that percentage alone. It turns on whether fewer older people, in poorer postcodes, pick up E. coli and Klebsiella in the first place.

Arora told the public to take antibiotics only when a clinician has said so, and to use the vaccines they are eligible for. That is the part of the 2025 file that the 10.7% use cut cannot substitute.

Frequently Asked Questions

What Is Bacteraemia and Why Does UKHSA Count It?

Bacteraemia means bacteria in the bloodstream, logged by UKHSA as patient episodes from blood cultures fed into its Second Generation Surveillance System. The AMR burden figure uses a fixed list of public-health pathogens and drug combinations, so a contaminant-heavy rise in coagulase-negative staphylococci can lift total blood-culture counts without moving that burden one-for-one.

What Did the Earlier UK AMR Plan Try to Cut in Human Use?

The 2019 to 2024 national action plan set a 15% reduction in human antibiotic use by 2024 from a 2019 baseline, an ambition later reduced to 5% in the 2024 to 2029 plan that also sits under a 20-year aim to contain AMR by 2040. England’s 2025 consumption figure is already 10.7% below 2019 on the ESPAUR measure.

How Does the AWaRe System Sort Antibiotics?

The World Health Organization created the AWaRe classification in 2017 and updates it every two years: Access drugs are first-line options with lower resistance pressure, Watch drugs have higher resistance potential and are stewardship targets, and Reserve drugs are last-resort. The UK uses an adapted list; the 2029 aim is 70% of total use from Access.

When Did England Make Candidozyma Auris Notifiable?

In April 2025 C. auris was added to schedule 2 of the Health Protection (Notification) Regulations 2010, so laboratories and clinicians must report it. Of 213 newly identified patients in 2025, 38 had invasive infection, and 127 were linked to declared hospital outbreaks concentrated in London and the South East.

Disclaimer: This article is news reporting and analysis of UK Health Security Agency surveillance figures for 2025, and is for information only. It is not medical advice, a diagnosis, or a guide to starting, stopping or sharing any antibiotic, antifungal or vaccine. Readers with symptoms, a current prescription, or questions about infection risk should speak to a GP, pharmacist or other qualified clinician before changing treatment. Case counts, rates and policy targets reflect the ESPAUR sources cited here and can be revised in later releases.

Harry is the editor and lead writer of KERALANEWS 24X7, which he owns and runs as an independent publication. After ten years in journalism as a reporter and then an editor, he treats a story as something that keeps its history rather than a page that is silently replaced. When a report is updated, the new material is added with the time it arrived, and earlier text that turned out to be wrong is corrected in the open under the site's public corrections policy rather than deleted. Readers in any time zone can see how a story developed. Publishing around the clock never shortens the checking: the primary filing, statement, transcript or dataset is located first, and every number is confirmed against it before it appears. The site covers news, business and technology, science and sports, and entertainment, lifestyle and travel, with auto and gaming reported to the same standard, all for an international readership. Reader mail goes to Harry rather than to a form, at support@keralanews247.com.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending